Combining low-dose anti-VEGFR2 antibody with anti-PD1 antibody treatment resulted in a delay in tumor growth and extended the survival time of mice afflicted with tumors (82).VEGF-A upregulates both LAYN and immune receptors in human CD8+ T cells such as TIGIT (82). This evidence concerns the gene VEGFA and neoplasm.